The Technical Analyst
Alpha Teknova, Inc. [TKNO]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Alpha Teknova, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-10.05% $1.799
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 73.44 mill |
| EPS: | -1.160 |
| P/E: | -1.550 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 40.82 mill |
| Avg Daily Volume: | 0.0124 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.550 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.03x |
| Company: PE -1.550 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.550 - 2.05 ( +/- 13.89%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-08-16 | Grossman Paul David | Buy | 4 386 | Common Stock |
| 2022-08-15 | Grossman Paul David | Buy | 4 826 | Common Stock |
| 2023-08-31 | Mcnamara Robert | Sell | 12 292 | Non-Qualified Stock Option (right to buy) |
| 2023-06-02 | Mcnamara Robert | Buy | 18 815 | Common Stock |
| 2023-08-31 | Mcnamara Robert | Sell | 18 815 | Common Stock |
| INSIDER POWER |
|---|
| 97.73 |
| Last 82 transactions |
| Buy: 28 174 863 | Sell: 2 326 861 |
Forecast:
16:00 - $1.799
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.799
Forecast 2: 16:00 - $1.799
Forecast 3: 16:00 - $1.799
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.799 (-10.05% ) |
| Volume | 0.0389 mill |
| Avg. Vol. | 0.0124 mill |
| % of Avg. Vol | 313.53 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TKNO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
TKNO
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
Last 10 Buy Signals
Latest Press Releases
2024-03-11 16:01:00 - Press Release
Teknova Reports Fourth Quarter And Full Year 2023 Financial Results
Full year 2023 total revenue was $36.7 million, down 11% year-over-year achieved 36% annual growth in the number of clinical solutions customers in 2023 company provides 2024 revenue guidance of $35-38 million
2024-02-21 16:01:00 - Press Release
Teknova To Report Fourth Quarter And Full Year 2023 Financial Results On March 11, 2024
Hollister, calif., feb. 21, 2024 (globe newswire) -- alpha teknova, inc. (“teknova”) (nasdaq: tkno), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the company will report its financial results for the fourth quarter and full year ended december 31, 2023, on monday, march 11, 2024, following the close of market.
2023-11-09 16:01:00 - Press Release
Teknova Reports Third Quarter 2023 Financial Results
Raised $22.9 million of equity capital, paid down $10.0 million of long-term debt third quarter 2023 total revenue was $8.2 million, down 24% from prior year expect 2023 revenue at the low end of previously announced guidance range of $37-40 million hollister, calif., nov. 09, 2023 (globe newswire) -- alpha teknova, inc. (“teknova” or the “company”) (nasdaq: tkno), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended september 30, 2023.
2023-10-26 08:00:00 - Press Release
Teknova To Report Third Quarter 2023 Financial Results On November 9, 2023
Teknova today announced that the company will report its financial results for the third quarter on thursday, november 9, 2023, following close of market.
2023-09-27 08:00:00 - Press Release
Teknova Launches Latest Proprietary Aav-tek™ product And End-to-end Plasmid Workflow Solutions To Streamline Therapeutic Process Development
Novel aex screening kit – now available for aav6 – and an expansive suite of high-quality reagents designed to expedite plasmid production will help accelerate breakthroughs across multiple aav constructs and workflows novel aex screening kit – now available for aav6 – and an expansive suite of high-quality reagents designed to expedite plasmid production will help accelerate breakthroughs across multiple aav constructs and workflows
Latest News
2024-02-21 16:01:00 - GlobeNewsWire
Teknova to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
HOLLISTER, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2023, on Monday, March 11, 2024, following the close of market.
2023-11-11 05:01:10 - Seeking Alpha
Alpha Teknova, Inc. (TKNO) Q3 2023 Earnings Call Transcript
2023-10-26 08:00:00 - GlobeNewsWire
Teknova to Report Third Quarter 2023 Financial Results on November 9, 2023
Teknova today announced that the Company will report its financial results for the third quarter on Thursday, November 9, 2023, following close of market.
2023-08-13 09:20:26 - Seeking Alpha
Alpha Teknova, Inc. (TKNO) Q2 2023 Earnings Call Transcript
Alpha Teknova, Inc. (NASDAQ:TKNO ) Q2 2023 Earnings Conference Call August 10, 2023 5:30 PM ET Company Participants Sara Michelmore - MacDougall Advisors Stephen Gunstream - President & Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Steven Mah - TD Cowen Matt Larew - William. Blair Paul Knight - KeyBanc Mark Massaro - BTIG Jacob Johnson - Stephens Operator Good day, and welcome to Teknova's Second Quarter 2023 Financial Results Conference Call.
2023-07-26 08:00:00 - GlobeNewsWire
Teknova to Report Second Quarter 2023 Financial Results on August 10, 2023
HOLLISTER, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2023, on Thursday, August 10, 2023, following the close of market.
2023-05-25 08:00:00 - GlobeNewsWire
Teknova to Participate in Upcoming Investor Conference
HOLLISTER, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will present and host individual and small group meetings at the following upcoming investor conference:
2023-05-13 13:57:06 - Seeking Alpha
Alpha Teknova, Inc. (TKNO) Q1 2023 Earnings Call Transcript
Alpha Teknova, Inc. (NASDAQ:TKNO ) Q1 2023 Earnings Conference Call May 10, 2023 5:30 PM ET Company Participants Jennifer Henry - Senior Vice President of Marketing Stephen Gunstream - President & Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Madeline Mollman - William Blair Steven Mah - TD Cowen Operator Good day, and welcome to the Teknova First Quarter 2023 Financial Results Call. [Operator Instructions] Please be advised that today's conference is being recorded.
2023-05-10 08:00:00 - GlobeNewsWire
Teknova to Present Data on Novel Products to Accelerate the Development of AAV Therapies at ASGCT 2023 Annual Meeting
Company will share their latest findings for custom product innovations aimed at addressing key gene therapy bioprocessing bottlenecks Company will share their latest findings for custom product innovations aimed at addressing key gene therapy bioprocessing bottlenecks
2023-04-26 08:00:00 - GlobeNewsWire
Teknova to Report First Quarter 2023 Financial Results on May 10, 2023
HOLLISTER, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, following the close of market.
2023-04-07 10:42:05 - Zacks Investment Research
Down -48.43% in 4 Weeks, Here's Why You Should You Buy the Dip in Alpha Teknova (TKNO)
Alpha Teknova (TKNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.